Centus Settles US Litigation Over Avastin

Agrees To Resolve Bevacizumab Patent Case With Genentech

Centus Biotherapeutics and Roche’s Genentech have agreed to settle US patent litigation over the biosimilars firm’s FKB238 proposed bevacizumab rival to Avastin.

Legal Settlement Gavel
Centus and Genentech have settled US litigation over bevacizumab • Source: Alamy

More from Legal & IP

More from Generics Bulletin